Abstract
Ischemic heart disease (IHD), diabetes, cancer and dementia share features of age-associated metabolic dysfunction. We hypothesized that metabolic diversity explains the diversity of morbidity later in life.
Methods We analyzed data from the UK Biobank (N = 329,908). A self-organizing map (SOM, an artificial neural network) was trained with 51 metabolic traits adjusted for age and sex. The SOM analyses produced six subgroups that summarized the multi-variable metabolic diversity. The subgroup with the lowest adiposity and disease burden was chosen as the reference. Hazard ratios (HR) were modeled by Cox regression (P < 0.0001 unless otherwise indicated). Enrichment of multi-morbidity over random expectation was tested by permutation analysis.
Results The subgroup with the highest sex hormones was not associated with IHD (HR = 1.04, P = 0.14). The subgroup with high urinary excretion without kidney stress (HR = 1.24) and the subgroup with the highest apolipoprotein B and blood pressure (HR = 1.52) were associated with IHD. The subgroup with high adiposity, inflammation and kidney stress was associated with IHD (HR = 2.11), cancer (HR= 1.29), dementia (HR = 1.70) and mortality (HR = 2.12). The subgroup with high triglycerides and liver enzymes was at risk of diabetes (HR = 15.6). Paradoxical enrichment of multimorbidity in young individuals and in favorable subgroups was observed.
Conclusions These results support metabolic diversity as an explanation to diverging morbidity and demonstrate the potential value of population-based metabolic subgroups as public health targets for reducing aggregate burden of chronic diseases in ageing populations.
Key messages
We introduced six data-driven subgroups of the UK Biobank as a high-dimensional model of metabolic diversity and disease risk within a human population.
Three subgroups captured features of the classical cardiometabolic spectrum with stratification along cholesterol and blood pressure, kidney or liver dysfunction and systemic inflammation.
Two novel subgroups of high sex hormones and high urinary excretion were observed.
We defined a new concept of multimorbidity enrichment.
nexpected patterns of multimorbidity indicated that metabolically “healthy” individuals with one cardiometabolic disease may be at a disproportional synergistic risk of co-morbidity.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
This study is based on data from UK Biobank cohort.
Funding Statement
This work was supported by the NHMRC grant GNT1157281. MAK was supported by a research grant from the Sigrid Juselius Foundation, Finland.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
UK Biobank obtained informed consent from each participant, and ethical approval was granted by the National Information Governance Board for Health and Social Care and North West Multi-centre Research Ethics Committee (11/NW/0382). The current study is approved by the UK Biobank under application number 29890.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data will be made available through application to the UK Biobank.
